Progenesis QI Software Acquisition

The FDA Office of Acquisition and Grant Services seeks one commercial perpetual software license for Progenesis QI, with quotations due May 25, 2026 at 1:00 PM Eastern Time and questions due by May 19, 2026. Award will be made on a Lowest Price Technically Acceptable (LPTA) basis.

Place of performance is FDA/CDER/OPQ/OPQR in St. Louis, Missouri. The software must support LC-MS data analysis workflows for complex drugs research and regulatory science initiatives, with required capabilities including vendor-independent data import, automated end-to-end processing, retention time alignment, peak picking, deconvolution, normalization, multivariate statistical analysis, and compound identification. The application must operate as a 64-bit Windows 11-compatible installation within FDA on-premises environments. Offerors must be authorized resellers or servicing agents and must provide technical documentation demonstrating compliance with Section 508 accessibility standards. The scope includes delivery of software, activation credentials, and applicable commercial documentation; it excludes system development, hosting services, contractor access to FDA systems, and ongoing managed services. Software delivery is required within 90 calendar days of award, with installation and updates provided during the one-year contract period. Payment is firm-fixed-price on a Net 30 basis after government acceptance through the Department of Treasury's Invoice Processing Platform. Pricing must remain valid through June 30, 2026. Standard FAR and HHSAR clauses apply, including federal compliance, labor standards, equal opportunity, and cybersecurity requirements. NAICS is 5132 (Software Publishers); PSC is DA10 (IT and Telecom—Business Application/Application Development Software as a Service). Submit quotations electronically to Roosevelt Walker, Contracting Officer, at roosevelt.walker@fda.hhs.gov.